The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body. Here, the inventor(s) developed a system for emission of therapeutic doses of UV light via a catheter, capsule, endoscope, tube or port that can be used to manage internal infections and inflammatory conditions inside a patient.

Systems for enabling delivery of very high peak power laser pulses through optical fibers for use in ablation procedures preferably in contact mode. Such lasers advantageously emit at 355 nm wavelength. Other systems enable selective removal of undesired tissue within a blood vessel, while minimizing the risk of damaging the blood vessel itself, based on the use of the ablative properties of short laser pulses of 320 to 400 nm laser wavelength, with selected parameters of the mechanical walls of the tubes constituting the catheter, of the laser fluence and of the force that is applied by the catheter on the tissues. Additionally, a novel method of calibrating such catheters is disclosed, which also enables real time monitoring of the ablation process. Additionally, novel methods of protecting the fibers exit facets are disclosed.

Systems for enabling delivery of very high peak power laser pulses through optical fibers for use in ablation procedures preferably in contact mode. Such lasers advantageously emit at 355 nm wavelength. Other systems enable selective removal of undesired tissue within a blood vessel, while minimizing the risk of damaging the blood vessel itself, based on the use of the ablative properties of short laser pulses of 320 to 400 nm laser wavelength, with selected parameters of the mechanical walls of the tubes constituting the catheter, of the laser fluence and of the force that is applied by the catheter on the tissues. Additionally, a novel method of calibrating such catheters is disclosed, which also enables real time monitoring of the ablation process. Additionally, novel methods of protecting the fibers exit facets are disclosed.

Systems and methods are disclosed for transporting a transport target across a membrane that is impermeable or semi-permeable to the transport target via artificially created microchannels or through hypodermic microneedles. The transport target can be a medicant and the membrane can be a stratum corneum layer of skin. The transport is enhanced by the application of ultrasound energy having a high peak intensity, which generates an inertial cavitation effect, an acoustic streaming effect, or both.

A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed light beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A treatment method is disclosed capable of reducing the burden on a patient and enhancing the effect of killing tumor cells. A treatment method for killing a tumor cell, the method including inserting a catheter into a main artery of an organ having the tumor cell, administering an antibody-photosensitive substance into a vein before the inserting of the catheter, inserting an optical fiber into the catheter, reducing an influence of blood in the artery on a near-infrared ray, irradiating at least one of a tumor, the vicinity of the tumor, or a regional lymph node with a first near-infrared ray by the optical fiber, and irradiating an antibody-photosensitive substance bound to a tumor cell membrane in the tumor cell with a second near-infrared ray having a shorter wavelength than that of the first near-infrared ray.

An ingestible capsule arranged, in use, to cross a human stomach for carrying out a phototherapic treatment arranged to combat an infection due to the presence of the bacterium Helicobacter pylori, said ingestible capsule comprising at least one primary light source arranged to emit an electromagnetic phototherapic wave having a wavelength .sub.1, at least one auxiliary light source arranged to emit an electromagnetic phototherapic wave having a wavelength .sub.2, a wrapper arranged to contain said or each primary light source and said or each auxiliary light source, said wrapper being at least partially transparent to said wavelengths .sub.1 and .sub.2, a control unit arranged to selectively activate said or each primary light source and/or said or each auxiliary light source, and at least one energy source arranged to provide energy for feeding said control unit and/or said light sources. In particular, 400 nm<.sub.1<525 nm and 525 nm<.sub.2<650 nm. Furthermore, said control unit is configured to receive an information of position reporting in real time an area of said stomach crossed by said ingestible capsule; to determine, known said information of position, a wavelength, a dosage and a duration of administration of said electromagnetic phototherapic waves for an optimal phototherapic treatment of said area of said stomach; to selectively activate said or each primary light source and/or said or each auxiliary light source to provide said optimal phototherapic treatment of said area of said stomach.

A bandage and a method of treating a wound with the bandage is provided. The method includes the steps of applying a photosensitive dye to the wound; covering the wound with a bandage; and applying a light to the dye such that the dye generates a reactive oxygen species.

The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body. Here, the inventor(s) developed a system for emission of therapeutic doses of UV light via a catheter, capsule, endoscope, tube or port that can be used to manage internal infections and inflammatory conditions inside a patient.